Q1 Earnings Forecast for Teleflex Issued By Wolfe Research

Teleflex Incorporated (NYSE:TFX) – Analysts at Wolfe Research issued their Q1 2026 earnings estimates for Teleflex in a research note issued on Wednesday, March 4th. Wolfe Research analyst M. Polark forecasts that the medical technology company will post earnings of $1.33 per share for the quarter. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Wolfe Research also issued estimates for Teleflex’s Q2 2026 earnings at $1.51 EPS, Q3 2026 earnings at $2.48 EPS, Q4 2026 earnings at $3.21 EPS, FY2026 earnings at $8.25 EPS, Q1 2027 earnings at $2.60 EPS, Q2 2027 earnings at $2.90 EPS, Q3 2027 earnings at $3.11 EPS, Q4 2027 earnings at $3.61 EPS, FY2027 earnings at $12.19 EPS, FY2028 earnings at $13.71 EPS, FY2029 earnings at $15.36 EPS and FY2030 earnings at $17.14 EPS.

Several other research firms also recently commented on TFX. Needham & Company LLC lifted their price target on shares of Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen downgraded shares of Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Monday, December 29th. Truist Financial lifted their price objective on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a report on Thursday, December 18th. Finally, Zacks Research cut Teleflex from a “hold” rating to a “strong sell” rating in a report on Monday, March 2nd. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Teleflex currently has an average rating of “Hold” and an average target price of $140.83.

Teleflex Stock Performance

NYSE:TFX opened at $113.61 on Monday. The company has a market capitalization of $5.02 billion, a price-to-earnings ratio of -5.53, a PEG ratio of 0.71 and a beta of 0.87. The business has a 50 day moving average of $110.79 and a 200 day moving average of $118.49. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.54 and a quick ratio of 2.01. Teleflex has a 1-year low of $100.18 and a 1-year high of $143.32.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $912.57 million. During the same period in the prior year, the firm posted $3.89 earnings per share. The business’s revenue was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, March 6th. This represents a $1.36 annualized dividend and a dividend yield of 1.2%. Teleflex’s payout ratio is -6.62%.

Institutional Trading of Teleflex

Several large investors have recently added to or reduced their stakes in TFX. Russell Investments Group Ltd. grew its holdings in shares of Teleflex by 23.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 83,388 shares of the medical technology company’s stock worth $9,870,000 after acquiring an additional 15,935 shares during the period. Public Sector Pension Investment Board lifted its stake in shares of Teleflex by 24.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 188,208 shares of the medical technology company’s stock valued at $23,029,000 after purchasing an additional 37,539 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Teleflex by 113.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 58,047 shares of the medical technology company’s stock valued at $7,366,000 after purchasing an additional 30,912 shares during the period. Creative Planning boosted its position in shares of Teleflex by 76.5% during the second quarter. Creative Planning now owns 10,338 shares of the medical technology company’s stock valued at $1,224,000 after purchasing an additional 4,480 shares in the last quarter. Finally, Savant Capital LLC boosted its position in shares of Teleflex by 81.0% during the third quarter. Savant Capital LLC now owns 18,248 shares of the medical technology company’s stock valued at $2,233,000 after purchasing an additional 8,166 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.